Novartis AG (NVS)
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General